Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TAVR: The Need for a Pacemaker Is Associated with Mortality

Courtesy of Dr. Carlos Fava.

 

TAVR: The Need for a Pacemaker

After a transcatheter aortic valve replacement (TAVR), the incidence of permanent pacemaker (PPM) implantation ranges from 6% to 30% in different studies, depending on the valve type used. This is due to trauma, ischemia, haemorrhage, and atrioventricular node and infranodal tissue oedema, provoking ventricular dyssynchrony similar to that caused by complete left bundle branch block. The evolution of patients requiring permanent pacemaker after TAVR has not been fully studied.

 

This study included 9785 patients from 229 hospitals; 651 (6.65%) of these subjects received a permanent pacemaker.

 

Patients receiving a permanent pacemaker were more frequently men with a higher STS predicted risk of mortality score (7.3% vs. 6.7%; p = 0.004), who received aortic valvuloplasty less often and presented more conduction defects in the baseline echocardiogram.

 

During the procedure, patients requiring a permanent pacemaker received larger valves, with higher oversizing. Mean time between valve replacement and permanent pacemaker implantation was three days.

 

Self-expanding valves (CoreValve) required the implantation of permanent pacemakers more frequently than balloon-expandable valves (E. Sapiens). Extreme-risk or inoperable patients required a permanent pacemaker more frequently than high-risk patients. Hospital stays were longer for patients requiring a PPM.

 

At a year, the need for a permanent pacemaker was associated with an increase in mortality (24.1% vs. 19.6%; hazard ratio [HR]: 1.31; 95% confidence interval [CI]: 1.09 to 1.58) and an increase in a composite of mortality and heart failure (37.3% vs. 28.5%; HR: 1.33; 95% CI: 1.13 to 1.56).

 

The following were predictors of the need for permanent pacemaker implantation after TAVR at 30 days:

  • age;
  • prior conduction defect;
  • aortic valve area ≤0.75 cm2;
  • use of self-expanding valves.

 

Conclusion

The need for a pacemaker is a common complication following TAVR, and it is associated with higher mortality and hospitalization due to heart failure at one year.

 

Editorial

Prior studies argued that permanent pacemaker implantation did not affect outcomes. This study, however, proves the opposite: it is associated to a hard event, mortality, and a higher need for hospitalization due to heart failure. This also increases healthcare costs.

 

The upcoming challenge lies in the development of devices that lower the need for a permanent pacemaker while maintaining or improving current performance.

 

Courtesy of Dr. Carlos Fava. Buenos Aires Favaloro Foundation, Argentina.

 

Original title: Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement. Analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry.

Reference: Opeyemi O. FadaHunsi, et al. J Am Coll Cardiol Intv 2016;9:2189-99.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

Beyond TAVI: Cardiac Rehabilitation as a Determinant of Clinical Outcomes

Aortic stenosis is an increasingly prevalent condition associated with population aging, with a prevalence of approximately 3.4% in individuals over 75 years of age...

Comparative outcomes between transaxillary approach and thoracotomy-based approaches in TAVI with alternative access

TAVI has become the standard treatment for high-risk aortic stenosis. When transfemoral access is not feasible (approximately 10–15%), alternative approaches are used: transaxillary (subclavian...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...